MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

FDA Grants Thermo Fisher Scientific 510(k) Clearance for SeCore HLA Typing Kit as Companion Diagnostic for T-Cell Receptor Therapy in Synovial Sarcoma

NextEdge Admin

06 Aug 2024

2 min 1 sec

companion diagnostic,synovial sarcoma,Adaptimmune

Thermo Fisher Scientific Inc. announced that its SeCore™ CDx HLA A Sequencing System has received 510(k) clearance from the FDA as a companion diagnostic for TECELRA® (afamitresgene autoleucel), Adaptimmune’s T-cell receptor (TCR) therapy. TECELRA is approved for adults with unresectable or metastatic synovial sarcoma who have previously undergone chemotherapy, are positive for HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P, and whose tumors express the MAGE-A4 antigen.

Cancer immunotherapies, including TCR therapies, are critical for treating metastatic or unresectable tumors. TCRs interact with specific human leukocyte antigen (HLA) proteins to trigger immune responses, making high-resolution HLA typing essential for identifying patients likely to benefit from treatments like TECELRA.

Originally linked to transplant diagnostics for reducing immune-mediated rejection, HLA typing has broader implications for the immune system and various conditions. Thermo Fisher’s Transplant Diagnostics leverages its expertise in immunology to innovate and improve patient outcomes across therapeutic areas.

“We are excited to extend the use of our SeCore CDx HLA A Sequencing System to include TECELRA, aiding clinicians in identifying suitable patients for this novel treatment,” said Tina Liedtky, president of Transplant Diagnostics, Thermo Fisher Scientific. “We aim to collaborate with companies like Adaptimmune to enhance patient access to groundbreaking therapies that improve quality of life.”